

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2018

DESPATCHED ON 11TH SEPTEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1,A3; B35, B62; Cw4, Cw9; DR1, DR10; DQ5, DQ-

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	11	11	11	11	24	24	24	24	20	20	20	20				
Positive	0	0	0	0	0	0	0	0	1	3	0	6				
Negative	11	11	11	11	24	24	24	24	19	17	20	14				
NT	1	1	1	1	1	1	1	1	5	5	5	5				
% Positive	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	5.0%	15.0%	0.0%	30.0%				
% Negative	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	95.0%	85.0%	100.0%	70.0%				
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Not Assessed				
HLA Antibody Specificity (Defined By CDC)	B7 B27 Multi	B7	DR52	A10	B7 B27 Multi	B7	DR52	A10	B7 B27 Multi	B7	DR52	A10				
				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
112	YES			NT	NT	NT	NT									Low cell viability
119	YES			Negative	Negative	Negative	Negative									
120		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
133		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	
139	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	
143		YES						Negative	Negative	Negative	Negative					
147	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
154		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
157	YES			Negative	Negative	Negative	Negative									
159		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
163		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
189	YES			Negative	Negative	Negative	Negative									
190		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
193		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
194		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
195		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
197		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	
209		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
216		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
229	YES			Negative	Negative	Negative	Negative									
232		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
235	YES			Negative	Negative	Negative	Negative									
238	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
239	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
245	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	YES	YES	YES	Negative	Negative	Negative	Negative									
260		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
292		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Late delivery. Low cell viability
293		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
297		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2018

DESPATCHED ON 11TH SEPTEMBER 2018

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	NT	NT	NT	NT									60		
119	1	2	1	1									95		
120					1	1	1	1	1	1	1	1		100	100
133					2	2	2	2	2	6	2	6	95	95	95
139	1	1	1	1	1	1	1	1	1	6	1	6	99	99	90
143					1	1	1	1						90	
147	1	1	1	1	1	1	1	1	1	1	1	1	100	100	100
154					1	1	1	1	1	1	1	2	100	100	90
157	1	1	1	1									100		
159					1	1	1	1	1	1	1	6		90	90
163					1	1	1	1	1	1	1	1		95	95
169					1	1	1	1	1	1	1	1		98	97
189	1	1	1	1									90		
190					10%	10%	10%	20%	NT	NT	NT	NT		90	
193					-	-	-	-	NT	NT	NT	NT		90	
194					1	1	1	1	1	1	1	1		98	90
195					2	2	2	2	NT	NT	NT	NT		80	
197					-	-	-	-	-	Strong	-	Strong		80	80
209					-	-	-	-	-	-	-	2		90	90
216					1	1	1	1	1	1	1	1		95	95
229	-	-	-	-									90		
232					0%	0%	0%	0%	75%	0%	0%	0%		80	80
235	1	1	1	1									85		
238	1	1	1	1	1	1	1	2	NT	NT	NT	NT	95	95	
239	-	-	-	-	-	-	-	-	-	-	-	-	96	96	96
245	1	1	1	1	1	1	1	1	1	1	1	1	100	100	100
252	1	1	1	1					2	1-2	1	1	70		80
260					-	-	-	-	-	-	-	-		90	80
292					NT	NT	NT	NT	NT	NT	NT	NT		25	15
293					-	-	-	-	-	-	-	-		80	80
294					0	0	0	0	0	0	0	0		95	80
297					1	1	1	1	1	1	1	1		90	90

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2018

DESPATCHED ON 11TH SEPTEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1,A3; B35, B62; Cw4, Cw9; DR1, DR10; DQ5, DQ-

				Summary of Results												
				PBL				T-Cells				B-Cells				
				11	11	11	11	22	22	22	22	18	18	18	18	
Total tested				0	0	0	0	0	0	0	0	0	0	0	0	
Positive				11	11	11	11	22	22	22	22	18	18	18	18	
Negative				1	1	1	1	1	1	1	1	6	6	6	6	
NT				0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
% Positive				100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
% Negative				Negative				Negative				Negative				
Consensus				B7 B27 Multi	B7	DR52	A10	B7 B27 Multi	B7	DR52	A10	B7 B27 Multi	B7	DR52	A10	
HLA Antibody Specificity (Defined By CDC)				With DTT				With DTT				With DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
112	YES			NT	NT	NT	NT									Low cell viability
119	YES			Negative	Negative	Negative	Negative									
120		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Low B-cell viability
133		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
139	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Low B-cell viability
143		YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	
147	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
157	YES			Negative	Negative	Negative	Negative									
159		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
163		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
189	YES			Negative	Negative	Negative	Negative									
190		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Late delivery. Low cell viability
193		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	
194		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
195		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	
197		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
209		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
216		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
229	YES			Negative	Negative	Negative	Negative									
235	YES			Negative	Negative	Negative	Negative									Late delivery. Low cell viability
238	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
245	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
252	YES	YES	YES	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	
260		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
262	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
292		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Late delivery. Low cell viability
293		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Late delivery. Low cell viability
297		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2018

DESPATCHED ON 11TH SEPTEMBER 2018

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	NT	NT	NT	NT									60		
119	1	1	1	1									95		
120					1	1	1	1	1	1	1	1		100	100
133					2	2	2	2	2	2	2	2			
139	1	1	1	1	1	1	1	1	1	1	1	1	99	99	90
143					1	1	1	1	NT	NT	NT	NT		90	
147	1	1	1	1	1	1	1	1	1	1	1	1	100	100	100
157	1	1	1	1									100		
159					1	1	1	1	1	1	1	1		90	90
163					1	1	1	1	1	1	1	1		95	95
169					1	1	1	1	1	1	1	1		98	97
189	1	1	1	1									90		
190					10	10	10	15	NT	NT	NT	NT		90	
193					-	-	-	-	NT	NT	NT	NT		90	
194					1	1	1	1	1	1	1	1		98	90
195					2	2	2	2	NT	NT	NT	NT		80	
197					-	-	-	-	-	-	-	-		80	80
209					-	-	-	-	-	-	-	-		90	90
216					1	1	1	1	1	1	1	1		95	95
229	-	-	-	-									90		
235	1	1	1	1									85		
238	1	1	1	1	1	1	1	1	NT	NT	NT	NT	95	95	
245	1	1	1	1	1	1	1	1	1	1	1	1	100	100	100
252	1	1	1	1					2	1-2	1	1	70		80
260					-	-	-	-	-	-	-	-		90	80
262	1	1	1	1	1	1	1	1	1	1	1	1	90	90	90
292					NT	NT	NT	NT	NT	NT	NT	NT		25	15
293					0	0	0	0	0	0	0	0		80	80
294					0	0	0	0	0	0	0	0		95	80
297					1	1	1	1	1	1	1	1		90	90